Comparative Pharmacology
Head-to-head clinical analysis: KELNOR 1 50 versus N E E 1 35 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR 1 50 versus N E E 1 35 28.
KELNOR 1/50 vs N.E.E. 1/35 28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol provides estrogenic activity, suppressing gonadotropin release; norethindrone acetate provides progestational activity, inhibiting ovulation and causing cervical mucus thickening.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin (FSH and LH) release, preventing ovulation. Also cause cervical mucus thickening and endometrial changes.
One tablet (norethindrone 1 mg/ethinyl estradiol 50 mcg) orally once daily, taken at the same time each day for 21 days, followed by 7 days of placebo.
One tablet orally once daily for 28 days; each tablet contains norethindrone 1 mg and ethinyl estradiol 35 mcg.
None Documented
None Documented
Ethinyl estradiol: biphasic, terminal half-life 13-27 hours (mean ~17 h); norethindrone: monoexponential, half-life 5-14 hours (mean ~8 h). Steady-state achieved after 3-5 days. Accumulation may occur in patients with hepatic impairment.
Ethinyl estradiol: ~15-19 hours (linear pharmacokinetics); Norethindrone: ~7-9 hours (terminal half-life; steady-state achieved within 5-7 days)
Renal: ~50% (as metabolites, primarily ethinyl estradiol glucuronide and sulfate conjugates; norethindrone metabolites). Fecal: ~35% (biliary excretion of conjugates followed by hydrolysis and elimination). Unchanged drug: <5%.
Renal: ~50-60% (metabolites, primarily glucuronide conjugates); Fecal: ~30-40% (biliary excretion of metabolites); Unchanged drug: <5%
Category C
Category C
Oral Contraceptive
Oral Contraceptive